Imagine it is three months after your mother’s stroke. The family group chat has turned into a recovery command center: therapy times, a borrowed walker, questions for the neurologist. Then a cousin who lives in Russia posts a photo of nasal drops called Semax and says doctors there use it after strokes. A quick search turns up the same name on a U.S. research-peptide site.
It is a fair question, and the honest answer has two parts: what the Russian studies found, and why that still does not make a research vial part of your mother’s recovery plan.
What Russian stroke studies reported
Semax is a synthetic peptide built from a fragment of the hormone ACTH. Russian researchers call it a domestic drug and have tested it in stroke patients for decades.
In a 1997 study, 30 patients in the acute phase of an ischemic stroke received Semax on top of standard intensive care. They were compared with 80 patients whose strokes were similar in severity and location and who got conventional treatment. The authors reported faster recovery of some neurological functions, especially movement. The abstract describes a matched comparison group; it does not describe random assignment or blinding.
A 2018 study followed 110 people after ischemic stroke who started rehabilitation either earlier, around three months, or later, around seven months. Each group was split into patients who received Semax and patients who did not. Those given Semax had higher blood levels of BDNF, a growth factor linked to brain plasticity, and better scores on a daily-living scale. The same paper also found that starting rehabilitation earlier was tied to better movement gains.
A 2018 meta-analysis of the Russian literature found eight studies with 654 patients suitable for review, but only three, with 181 patients, measured the same outcomes. Those pooled results favored Semax on stroke-severity and mobility scales in the first weeks. The authors’ own conclusion is the line worth remembering: a large, multicenter, double-blind trial still needs to be done, using a standard design.
What that evidence can and cannot do for your family
These are real clinical studies, which puts Semax ahead of many peptides sold online. They are also small, published mostly in Russian journals, and, by the meta-analysis authors’ own account, still waiting on the kind of large blinded trial that shows whether a drug truly changes recovery.
In the United States, Semax is not an FDA-approved medicine. Semax also appears on FDA’s compounding safety-risk page, where the agency cites possible immune reactions, impurity concerns, and little safety information for proposed routes of use. The pooled Russian studies used an intranasal solution given in the first weeks after a stroke. A U.S. research-catalog vial is sold for laboratory use, without that product’s standards or a care team watching how a stroke survivor responds.
What does have broad support is rehabilitation itself. MedlinePlus notes that stroke rehabilitation is recommended for anyone affected by stroke, that most people who take part in a program recover better than those who do not, and that earlier starts improve the chances of regaining lost skills.
A better use of the group chat. Write the Semax question down and bring it to your mother’s neurologist or rehab team. Ask what is driving her current plan, whether a clinical trial fits her situation, and how to protect her therapy hours. Do not add a research product to her routine on your own; her care team knows her other medicines and risks. Keep the cousin’s photo as a question, not a prescription.
Not medical advice.
Sources
- Gusev et al., Zhurnal Nevrologii i Psikhiatrii (1997): Semax in acute ischemic stroke, 30 treated vs 80 comparison patients (PubMed 11517472)
- Gusev et al., Zhurnal Nevrologii i Psikhiatrii (2018): Semax, rehabilitation timing, BDNF and daily-living scores in 110 patients (PubMed 29798983)
- Shmonin et al., Bulletin of Rehabilitation Medicine (2018): meta-analysis of Semax in acute stroke
- FDA page on bulk substances flagged for compounding risks: Semax (heptapeptide) entry
- MedlinePlus: Stroke rehabilitation
Related reading
- Semax focus claims and the human evidence
- Thymosin alpha-1: approved overseas, not in the U.S.
- How to read FDA bulk-compounding safety notes
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-12 PT. Not medical advice.